Results 1 - 10 of 39
Results 1 - 10 of 39. Search took: 0.02 seconds
|Sort by: date | relevance|
[en] For the pulsed neutron generation, a low energy Mather-type Plasma Focus Device (APL-PFD1) was designed and examined. Snow-Plow model was applied for electrode design. Stored bank energy and discharge peak current of APL-PFD1 are 2.2kJ and 147kA respectively. Electrical diagnoses were consisted of high voltage probe and Rogowski loop. A simple CR-39 based Thomson Spectrometer was constructed and used for measurement of ion beam. X-ray intensity ratio method and ND filter covered camera were used in order to measure the characteristics of focused plasma. For continuum X-ray detection, Fe was used as a filter material for suppressing Cu- Kα line radiation. In this study, 100ns high voltage spikes that indicate pinched plasma was observed with good reproducibility. In case of Ar discharge, operating pressure band is 1.0∼3.0Torr. The operating pressure of deuterium discharge is 1.6∼1.7Torr. Due to the wide operating pressure and high atomic mass number, pressure dependency of current sheath speed is easily determined from tube voltage signal in Ar discharge. At optimum pressure, the most bright plasma column was generated. Point-like Ion track was observed in deuterium discharge, however no track was observed in Ar discharge. The deuterium plasma temperature estimated from X-ray observations was about 3keV. According to the energy sailing law, 4.3x108 /shot neutron yield of APLPFD1 can be expected
[en] Irradiation of 20 mg of natural Dy(NO3)3 in a neutron flux of 2 X1013 n/cm2 sec for 4 hours gave 5.76 Ci of 165Dy (specific activity, 610 mCi/mg Dy) with high radionuclidic purity (>99.9%). 165Dy-MA was prepared in a quantitative yield by reacting the aqueous solution of 165Dy(NO3)3 with sodium borohydride solution in 0.2N NaOH. Coulter particle analyzer exhibited mean particle size of 2.6 μm (range 1 ∼ 6 μm). Even though the 165Dy-MA suspension in saline was stored at 37 .deg. C for 24 hours of autoclaved at 121 .deg. C for 30 minutes, there was no significant change in particle size and leakage problem indicating the prepared 165Dy-MA is sufficiently stable. In-vivo retention studies were carried out by administering 165Dy-MA into the knee joint space of normal rabbits. Gamma camera analysis showed high retention in joint space of normal rabbits. Gamma camera analysis showed high retention in joining space even at 24 hours after administration (>99.9%) The ease with which the165Dy-MA can be made in the narrow size range and their high in vitro and vivo stability make them attractive agents for radiation synovectomy.
[en] Various TSH RIA kit components were prepared. Conditions for 125I labelling of h-TSH were optimized by diminishing the amount of chloramine-T, extending reaction time and lowering reaction temperature. Yield, specific activity, and immunological activity could be maintained moderately under such mild reaction conditions. The mixture of polyethyleneglycol (PEG) and second antibody worked effectively as a B/F separation agent. Even though the mixture was made with more diluted PEG and second antibody than those of using the sole component separately, the time required for the B/F separation was shorter in case of using the mixture. The sequential saturation technique was efficient than those of applying ordinary equilibrium saturation technique in assay sensitivity and assay precision points of view.
[en] Various experiments for the quality control of Tc-99m labelled radiopharmaceuticals such as Tc-99m-phytate, Tc-99m-MDP, Tc-99m-Tin Colloid, Tc-99m-DISIDA, Tc-99m-DTPA,Tc-99m-DMSA, Tc-99m-Gulcoheptonate, TC-99m-Pyrophosphate, Tc-99m-HSA, and Tc-99m-HAM were carried out. Labelling yield and radiochemical purity of each of the instant labelling kit of KAERI made were determined by means of radiochromatography. Biodistribution in mice and whole body or specific organ imagings of rabbits were also carried out and discussed the relationship between the data of biodistributions and radiochemical purities. Labelling yeilds were above 98% for almost all of the labelling kits. The radio-pharmaceuticals were accumulated at each target organ with moderate specifities. In case of radiochemical purity of above 98%, the biodistribution and gamma imagings were also better. The kits of MDP and DISIDA were stable at least for four moths while the other kits at least eight months. (Author)
[en] Among the pituitary hormones, a FSH radioimmunoassay procedure has been established. The labelling and the separation methods are suitable for a FSH radioimmunoassay. However, the gel filtration technique is superior to the starch gel electrophoresis in view of the simplicity, short separation time and the bindability of the purified labelled antigen to its antibody. For the separation of the free antigen from the antibody bound, the double antibody technique could be successfully applied.
[en] To develop 99mTc instant labelling kit of d,1-HMPAO and 131I labelled IMP for the regional cerebral blood flow scintigraphic use, d,1-HMPAO and IMP were synthesized. The former was prepared from 2,3-butadione monoxim and 2,2-dimethyl-1,3-propanediamine in the presence of cation exchange resin, and then selective reduction of imine bond with sodium borohydride followed by fractional crystallization of diastereometric mixture of HMPAO. The latter was prepared by condensation of p-iodophenylpropanone with isopropylamine, and then reduction of double bond with sodium borohydride. For the preparation of 99mTc labelled HSA, experiments on incorporation of bifunctional chelating agent of DTPA to HSA, establishment of optimal conditions of 99mTc labelling, determination of labelling yield and radiochemical purity, and examination of stability were carried out. (Author)
[en] To deveolp 99mTc instant labelling kits of dimercaptosuccinic acid (DMSA), glucoheptonic acid (GH), and tin colloid, molar ratios of the host compound to the stannous chloride, amount of the stannous chloride and pH were, respectively, controlled. The labelling yields and radiochemical purities were checked by means of a paper chromatography. Animal studies and clinical applications were also carried out. The results indicated that DMSA/SnCl2 2H2O 3/1(mole/mole), SnCl2 2H2O 410ug/ml/vial, pH 2.5, Ca GH/SnCl2 2H2O 53/1(mole/mole), SnCl2 2H2O 350 ug/ml/vial, pH 6.5, NaF 100ug/vial, SnCl2 2H2O 150 ug/ml/vial, pH. 5.6 etc, were optimal conditions for the preparation of DMSA-, GH-, and tin colloid-kits, respectively. (Author)
[en] To develop 131I-labelled m-iodobenzylguanidine (1311-MIBG), various experiments such as synthesis of MIBG, establishment of labelling conditions, determination of radiochemical purity, and examination of stability were carried out. 1) m-Iodobenzylguanidine (MIBG) sulfate was synthesized with a total yield of 62.4% by the condensation of m-iodobenzylamine hydrochloride with cyanamide via MIBG bicarbonate. Its physical properties, IR, 1H-NMR, and elemental analysis data were nearly identical to those of literature. 2) Freeze-dried or vacuum-dried kit vials were prepared from the mixture so as to contain MIBG (2 mg), ascorbic acid (10 mg), copper (II) sulfate (0.14 mg), and tin (II) sulfate (0.5 mg) per vial. Copper (I) catalyzed radioiodination of MIBG was carried out using kit vials and 0.01 M H2SO4 as solvent at 100 .deg. C for 30 min under nitrogen atmosphere (optimal conditions). Labelling yield was 98% and radiochemical purity was 99.5%, respectively. 3) Solid-phase radioiodination of MIBG was carried out at 155 .deg. C for 30 min using the prepared vials to contain MIBG (2 mg) and ammonium sulfate (10 mg). Duplicate reactions under the same conditions showed labelling yield of 95% and radiochemical purity of 99.5%. 4)131I-MIBG prepared either by catalytic or by solid-phase exchange method showed radiochemical purity of 99% even after 3 days storing at room temperature.
[en] (1) 125I labelling of insulin and the standardization of the labelled insulin for RIA use are well established. (2) A protocol of routine kit preparation is established. (3) Maximum two 100 tube kits can-be prepared from one batch. (4) The kits show steep dose-response curve. The expire date is usually 40 days after preparation.
[en] For the development of 99mTc Labelled 3-Iodo-2 , 4, 6-trimethyl-iminodiacetic acid (99mTc IOTIDA), various experiments such as synthesis of IOTIDA, establishment of labelling conditions, determination of radiochemical purity, examination of stability, and organ distribution of rat were carried out. 1) IOTIDA was synthesized with a total yield of 42% from the stating material of trimethylaniline via chloraacetylation, iodination, and condensation with iminodiacetic acid (IDA). 2) Freeze-dried instant labelling kits were prepared from aqueous solution (pH 5.8-6.0) so as to contain 40 mg IDA compound and 0.4 mg SnCl2 per vial. Labelling of the contents of kit vials with Na99mTcO4 exhibited formation of two kinds of complex (II) with time. Labelling yield and radiochemical purity were above 99.5% based on the two complexes overall. 3) 99mTc IOTIDA maintained high radiochemical purity of above 99% until 6 hours after preparation at room temperature. Instant labelling kits stored at 4 .deg. C for 6 month period also exhibited high labelling yield of above 99%. 4) Results obtained from animal experiments showed that most of the 99mTc IOTIDA was rapidly excreted through hepatobiliary track into the intestines but with negligible renal excretion.